Medicare will cover semaglutide (Wegovy) and tirzepatide (Zepbound) for their weight management indications for people with ...

Novo Nordisk and Eli Lilly said they've agreed to sell their blockbuster drugs Wegovy and Zepbound at a discount.

Certain blockbuster obesity drugs will be available for as little as $149 per month and more Medicare enrollees will have ...

The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with ...

Eli Lilly and Novo Nordisk agree to expand access and cut prices for Zepbound and Wegovy • Medicare to begin covering obesity ...

The agreements with pharma giants Eli Lilly and Novo Nordisk could bring the price of the GLP-1 injectables from roughly ...

The drugmaker said it would launch late-stage trials of the drug after participants lost as much as 20% of their body weight.

Medicare beneficiaries will soon be able to get obesity and Type 2 diabetes drugs for a $50 copay. But there are some ...

Eli Lilly & Co. and Novo Nordisk A/S secured deals with the Trump administration to slash prices for their blockbuster weight ...

(Reuters) -Shares of obesity drugmakers Eli Lilly and Novo Nordisk rose early on Thursday in anticipation of a White House ...

These stocks aren't popular right now, but their strong underlying businesses make them hot deals to pounce on.

MAHA advocates are skeptical of President Donald Trump's deal to lower drug prices for GLP-1 anti-obesity drugs.